Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Downing Renewables to be taken private in £175m deal

(Sharecast News) - Shares in Downing Renewables & Infrastructure Trust soared on Friday, after it agreed to be taken over by Bagnall Energy in a £175m deal. Bagnall is to pay 102.6p per share for Dore, which owns a portfolio of renewable energy and other infrastructure assets in the UK and northern Europe.

A near 24% premium to Thursday's closing price, the deal values Dore at £174.55m.

As at 1000 BST, shares in Dore were up 22% at 101.42p.

Hugh Little, Dore chair, said the deal was in the best interest of shareholders.

"Dore has consistently delivered on its investment strategy, resulting in a strong NAV and dividend performance, since IPO," he said.

"Despite this, and the proactive steps taken by the board to narrow its share price discount in recent years, the sustained horizon of economic and macro uncertainty has weighed on the share price, which has also limited the opportunities for further raising of new capital - and which may stretch into the mid to long-term."

James Watson, chair of Bagnall, said: "We are firm believers in the transformative power of renewable energy infrastructure, and the acquisition of Dore alights perfectly with Bagnall's long-term vision and commitment to the sector.

"The acquisition will enable [Dore] to achieve greater scale, success and operational efficiency. For too long, Dore's true value has not been reflected in its share price."

Bagnall - which is acquiring the business through its newly-formed vehicle Polar Nimrod - already owns just over 25% of Dore.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.